文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

异体“僵尸细胞”作为即用型疫苗用于术后癌症免疫治疗。

Allogeneic "Zombie Cell" as Off-The-Shelf Vaccine for Postsurgical Cancer Immunotherapy.

机构信息

Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.

NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Sichuan Institute for Drug Control, Chengdu, 611730, China.

出版信息

Adv Sci (Weinh). 2024 Apr;11(13):e2307030. doi: 10.1002/advs.202307030. Epub 2024 Jan 26.


DOI:10.1002/advs.202307030
PMID:38279587
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10987105/
Abstract

Allogeneic tumor cell vaccines provide off-the-shelf convenience but lack patient specificity due to heterogeneity in tumor antigens. Here, allogeneic tumor cell corpses are converted into "zombie cells" capable of assimilating heterogeneous tumor by seizing cancer cells and spreading adjuvant infection. This causes pseudo-oncolysis of tumors, transforming them into immunogenic targets for enhanced phagocytosis. It is shown that in postoperative tumor models, localized delivery of premade "zombie cells" through stepwise gelation in resection cavity consolidates tumor surgery. Compared to analogous vaccines lacking "seizing" or "assimilating" capability, "zombie cell" platform effectively mobilizes T cell response against residual tumors, and establishes immunological memory against tumor re-challenge, showing less susceptibility to immune evasion. Despite using allogeneic sources, "zombie cell" platform functions as generalizable framework to produce long-term antitumor immunity in different tumor models, showing comparable effect to autologous vaccine. Together, with the potential of off-the-shelf availability and personalized relevance to heterogenous tumor antigens, this study suggests an alternative strategy for timely therapy after tumor surgery.

摘要

同种异体肿瘤细胞疫苗提供了即用型的便利,但由于肿瘤抗原的异质性,缺乏患者特异性。在这里,同种异体肿瘤细胞尸体被转化为“僵尸细胞”,通过抓住癌细胞并传播佐剂感染,从而能够同化异质肿瘤。这导致肿瘤的假溶解,将其转化为增强吞噬作用的免疫原性靶标。结果表明,在术后肿瘤模型中,通过在切除腔中逐步凝胶化局部递送电预制的“僵尸细胞”,可巩固肿瘤手术。与缺乏“捕获”或“同化”能力的类似疫苗相比,“僵尸细胞”平台有效地调动了针对残留肿瘤的 T 细胞反应,并建立了对肿瘤再挑战的免疫记忆,对免疫逃逸的敏感性较低。尽管使用同种异体来源,但“僵尸细胞”平台作为通用框架,可在不同肿瘤模型中产生长期抗肿瘤免疫,其效果可与自体疫苗相媲美。总之,这种方法具有现货供应的潜力和对异质肿瘤抗原的个性化相关性,为肿瘤手术后的及时治疗提供了一种替代策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/30a9bfd7988e/ADVS-11-2307030-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/edb2e2630690/ADVS-11-2307030-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/6301588b7518/ADVS-11-2307030-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/a40261090319/ADVS-11-2307030-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/d4ed90ba6c57/ADVS-11-2307030-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/d0303aba7307/ADVS-11-2307030-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/8840158cc212/ADVS-11-2307030-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/30a9bfd7988e/ADVS-11-2307030-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/edb2e2630690/ADVS-11-2307030-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/6301588b7518/ADVS-11-2307030-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/a40261090319/ADVS-11-2307030-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/d4ed90ba6c57/ADVS-11-2307030-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/d0303aba7307/ADVS-11-2307030-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/8840158cc212/ADVS-11-2307030-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5277/10987105/30a9bfd7988e/ADVS-11-2307030-g004.jpg

相似文献

[1]
Allogeneic "Zombie Cell" as Off-The-Shelf Vaccine for Postsurgical Cancer Immunotherapy.

Adv Sci (Weinh). 2024-4

[2]
Tumor cell lysates as immunogenic sources for cancer vaccine design.

Hum Vaccin Immunother. 2014

[3]
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.

Blood. 2003-2-15

[4]
Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy.

Biomaterials. 2022-10

[5]
Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination.

Biomaterials. 2023-10

[6]
Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.

Anticancer Res. 2013-7

[7]
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.

J Clin Oncol. 2004-3-15

[8]
Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.

Clin Cancer Res. 2005-11-1

[9]
Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.

Acc Chem Res. 2020-10-20

[10]
Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.

Immunol Lett. 2000-9-15

引用本文的文献

[1]
Subcellular Organelle Targeting as a Novel Approach to Combat Tumor Metastasis.

Pharmaceutics. 2025-2-5

本文引用的文献

[1]
A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens.

Sci Transl Med. 2023-10-4

[2]
In situ hydrogel enhances non-efferocytic phagocytosis for post-surgical tumor treatment.

J Control Release. 2023-11

[3]
From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy.

Bioact Mater. 2023-8-14

[4]
Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation.

Nat Commun. 2023-7-26

[5]
Curbing Exosome Communications via Introducing Artificial Membrane Receptors for Metastatic Pancreatic Cancer Therapy.

Adv Mater. 2023-9

[6]
Modulation of Autophagy Direction to Enhance Antitumor Effect of Endoplasmic-Reticulum-Targeted Therapy: Left or Right?

Adv Sci (Weinh). 2023-8

[7]
A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors.

J Control Release. 2022-11

[8]
Immunogenic hydrogel toolkit disturbing residual tumor "seeds" and pre-metastatic "soil" for inhibition of postoperative tumor recurrence and metastasis.

Acta Pharm Sin B. 2022-8

[9]
Walking Dead Tumor Cells for Targeted Drug Delivery Against Lung Metastasis of Triple-Negative Breast Cancer.

Adv Mater. 2022-8

[10]
Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis.

ACS Nano. 2022-4-26

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索